| Literature DB >> 27188849 |
Justyna Kiszałkiewicz1, Wojciech J Piotrowski2, Dorota Pastuszak-Lewandoska1, Paweł Górski2, Adam Antczak3, Witold Górski2, Daria Domańska-Senderowska1, Monika Migdalska-Sęk1, Karolina H Czarnecka1, Ewa Nawrot1, Ewa Brzeziańska-Lasota4.
Abstract
Elevated COX-2 activity is associated with the development of chronic lung diseases leading to bronchial obstruction, including sarcoidosis. The aim of the study was to examine expression pattern of COX-2 messenger RNA (mRNA). Expression was performed by q-PCR method in bronchoalveolar lavage (BAL) cells and peripheral blood (PB) lymphocytes in sarcoidosis patients (n = 61) and control group (n = 30). Analysis of COX-2 mRNA expression level in BAL fluid and PB revealed downregulation in sarcoidosis and control groups. In PB lymphocytes, the statistically significant difference between patients and controls was observed (P = 0.003, Mann-Whitney U test), with higher expression in patients. There were no statistically significant differences between patients without and with parenchymal involvement (stages I vs. II-IV), between patients with acute vs. insidious onset of disease and between patients with abnormal vs. normal spirometry (P > 0.05, Mann-Whitney U test). Results suggest that expression of COX-2 mRNA in patients with pulmonary sarcoidosis is not related to clinical classifications.Entities:
Keywords: COX-2; biomarkers; expression; pulmonary sarcoidosis
Mesh：
Substances：
Year: 2016 PMID： 27188849 DOI： 10.1007/s10753-016-0362-y
Source DB: PubMed Journal: Inflammation ISSN： 0360-3997 Impact factor: 4.092